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Aims In the era of personalized medicine, it is of utmost importance to be able to identify subjects at the highest cardio-
vascular (CV) risk. To date, single biomarkers have failed to markedly improve the estimation of CV risk. Using
novel technology, simultaneous assessment of large numbers of biomarkers may hold promise to improve predic-
tion. In the present study, we compared a protein-based risk model with a model using traditional risk factors in
predicting CV events in the primary prevention setting of the European Prospective Investigation (EPIC)-Norfolk
study, followed by validation in the Progressione della Lesione Intimale Carotidea (PLIC) cohort.
...................................................................................................................................................................................................
Methods
and results
Using the proximity extension assay, 368 proteins were measured in a nested case–control sample of 822 individu-
als from the EPIC-Norfolk prospective cohort study and 702 individuals from the PLIC cohort. Using tree-based
ensemble and boosting methods, we constructed a protein-based prediction model, an optimized clinical risk
model, and a model combining both. In the derivation cohort (EPIC-Norfolk), we defined a panel of 50 proteins,
which outperformed the clinical risk model in the prediction of myocardial infarction [area under the curve (AUC)
0.754 vs. 0.730; P < 0.001] during a median follow-up of 20 years. The clinically more relevant prediction of events
occurring within 3 years showed an AUC of 0.732 using the clinical risk model and an AUC of 0.803 for the pro-
tein model (P < 0.001). The predictive value of the protein panel was confirmed to be superior to the clinical risk
model in the validation cohort (AUC 0.705 vs. 0.609; P < 0.001).
...................................................................................................................................................................................................
Conclusion In a primary prevention setting, a proteome-based model outperforms a model comprising clinical risk factors in
predicting the risk of CV events. Validation in a large prospective primary prevention cohort is required to address
the value for future clinical implementation in CV prevention.
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Introduction
Identification of asymptomatic people at the greatest cardiovascular
(CV) risk remains a major challenge in primary prevention.1,2
Clinically used risk algorithms, including the Framingham risk score,
pooled cohort equations, and Systemic Coronary Risk Evaluation
(SCORE) system, are based on traditional risk factors for CV disease
and predict future events with limited accuracy.3,4 Accordingly, a sub-
stantial proportion of the general population at risk remains unidenti-
fied until their first clinical event.2 Despite adding individual plasma
biomarkers such as pro-brain natriuretic peptide (BNP), high sensitiv-
ity troponins, and high sensitivity C-reactive protein (CRP) to clinical
risk engines, the overall improvement has been limited.3 This may be
explained by the fact that the vast majority of single markers are
selected based on specific pathophysiological concepts, which do not
reflect the true complexity of atherosclerosis. In fact, CV risk is the
result of an interplay between comorbidities (chronic inflammatory
diseases, metabolic derangements) and exogenous risk factors,
propagated by a variety of pathophysiological axes, comprising but
not limited to lipids, coagulation, and inflammation.5
Simultaneous assessment of a large number of plasma proteins
may hold a promise to further refine risk assessment.6 To this end, ei-
ther discovery proteomics, aiming to identify new diagnostic markers
or therapeutic targets, or targeted proteomics, aimed at quantifica-
tion of proteins of specific interest, can be applied.6 Widespread use
of proteomics has been precluded by labour intensiveness, high costs,
and the complex clinical interpretation of the bulky results. More re-
cently, these limitations have largely been resolved. Technical advan-
ces now allow for high-throughput proteomic analysis in a
reproducible and cost-effective manner.7 In parallel, advanced com-
putational modelling has facilitated the interpretation of large data
sets for clinical implementation.8,9 Using these innovations, a targeted
protein panel was found to modestly improve the prediction of inci-
dent atherosclerotic CV disease in primary prevention,10 whereas
Ganz et al.11 substantiated that targeted proteomics also outper-
formed refit Framingham in predicting recurrent coronary events. In
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.support, we recently identified two complementary protein signa-
tures predicting the presence of high-risk plaque and the absence of
coronary atherosclerosis in subjects referred for the analysis of angin-
al complaints,12 clearly outperforming the traditional risk algorithm.13
In the present study, we hypothesized that a protein-based risk
model can outperform prediction using traditional risk factors in the
primary prevention setting. Therefore, we tested the ability of a tar-
geted proteomics panel comprising 368 proteins, related to pathways
and/or risk factors involved in atherogenesis, to predict CV event risk
in a nested case–control sample of the European Prospective
Investigation (EPIC)-Norfolk population study,14 using advanced
machine learning techniques. The findings were subsequently vali-
dated in the independent, external primary prevention cohort
[Progressione della Lesione Intimale Carotidea (PLIC)].15
Methods
Study populations
The derivation cohort was a nested case–control sample derived from
the EPIC-Norfolk prospective population study, comprising 25 633 indi-
viduals recruited from general practices in the Norfolk area, UK.14 Study
participants aged between 39 and 79 years were enrolled between 1993
and 1997. At baseline, patients completed general health questionnaires
and a panel of measurements was performed. During follow-up, all
individuals were flagged for mortality at the UK Office of National
Statistics and vital status was ascertained for the entire cohort. Data on
all hospital contacts throughout England and Wales were obtained using
National Health Service numbers through linkage with the East Norfolk
Health Authority (ENCORE) database. Hospital records and death certif-
icates were coded by trained nosologists and categorized according to
the International Classification of Disease 10th revision (ICD-10). The
study protocol was approved by the Norwich District Health Authority
Ethical Committee. All individuals gave written informed consent. For the
current study, we selected 822 apparently healthy individuals in a nested
case–control sample from the EPIC-Norfolk study. Apparently healthy
individuals were defined as study participants who did not report a his-
tory of CV disease. A total of 411 individuals who developed an acute
myocardial infarction (either hospitalization or death with ICD code I21-
22 coded as the underlying cause) between baseline and follow-up
through 2016 were selected together with 411 apparently healthy indi-
viduals who remained free of any CV disease during follow-up
(Figure 1).16,17
The validation cohort was the PLIC cohort, a single-centre, observa-
tional, cross-sectional, and prospective study of subjects enrolled on a
voluntary basis in 1998–2000 and followed for 11 years on average in the
northern area of Milan.15 The 2606 Caucasian subjects who were
enrolled in the study underwent four periodic visits. Data about clinical,
pathological, familial, and pharmacological history and lifestyle habits
were collected based on medical records and self-reporting during these
visits. Blood samples were withdrawn, and subjects underwent carotid
Figure 1 Machine learning workflow of model construction and validation. AHT med, antihypertensive medication; BMI, body mass index; CV, car-
diovascular; EPIC, European Prospective Investigation; HDL-C, high-density lipoprotein cholesterol; PLIC, Progressione della Lesione Intimale
Carotidea; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
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ultrasound to assess the presence or absence of carotid vascular damage.
The presence of documented stenosis or vascular damage on aorta and
limb arteries was included in the definition of subclinical atherosclerosis.
For the validation cohort, 702 subjects were selected, of whom 351
developed atherosclerosis, comprising subclinical atherosclerosis and 44
subjects who suffered from a CV event, and 351 gender-matched con-
trols during follow-up (Figure 1). Cardiovascular events were defined as a
combined endpoint of coronary heart disease (myocardial infarction, un-
stable angina, coronary revascularization, silent ischaemia) and cerebro-
vascular disease (ischaemic stroke and transient ischaemic attack). This
study was approved by the ethics committee and was performed in ac-
cordance with the Declaration of Helsinki. All participating subjects
signed informed consent.
Biochemical analyses
In EPIC-Norfolk, non-fasting blood was drawn at baseline from study par-
ticipants, from which total cholesterol, high-density lipoprotein (HDL)
cholesterol, and triglycerides were determined with the RA1000 analyser
(Bayer Diagnostics, Basingstoke, UK). The Friedewald formula was used
for the calculation of low-density lipoprotein (LDL) cholesterol levels.18
After blood withdrawal, ethylene diamine tetra acetic acid (EDTA) sam-
ples were kept overnight at room temperature before transporting to
the EPIC-Norfolk laboratory for centrifugation. Hereafter, the remaining
plasma was stored at -80C for future analyses.
In the PLIC cohort, blood samples were collected after overnight fast-
ing. Samples were kept on ice after blood withdrawal and centrifuged
within 1 h at 3000 rounds per minute for 12 min (Eppendorf 5810R cen-
trifuge). Plasma samples were subsequently stored in 200 lL aliquots at
-80C. Since multiple aliquots were stored, multiple freeze/thaw cycles
were prevented. Total cholesterol, HDL cholesterol, triglyceride and glu-
cose levels were determined in serum samples with the Cobas Mira Plus
Analyser (Horiba, ABX, France). Again, the Friedewald formula was used
for the calculation of LDL cholesterol levels.18
In 2019, we selected cases and controls from both cohorts, where-
upon aliquots were thawed and plasma was transferred, on ice, to 96-
well plates. The 96-well plates were shipped to Olink proteomics AB
(Uppsala, Sweden) on dry ice for analysis using the proximity extension
assay technology. Levels of 368 proteins were measured from the CV II,
CV III, Cardiometabolic, and Inflammation panels. These panels were
selected for their known associations with CV disease. Cases and con-
trols were randomly distributed across plates and assays were performed
in a blinded fashion. Data are Normalized Protein eXpression values.
Using an internal extension control and an interpolate control, data qual-
ity is controlled and normalized. All assay validation data are available on
the manufacturer’s website (www.olink.com).
Statistical analysis
Data are presented as mean ± standard deviation for normally distributed
variables or median with inter-quartile range for skewed data.
Categorical variables are expressed as absolute number and percentages.
Independent sample t-tests and Mann–Whitney U tests were used where
appropriate. Two-sided P-values <_0.05 were considered statistically sig-
nificant. Data were analysed using R version 3.5.1 (R Foundation, Vienna,
Austria).
Model construction
A combination of stacking generalization framework,19,20tree-based en-
semble methods, and multiple gradient boosting classifiers21 was used to
best discriminate between cases and controls. Using these techniques,
explained in detail below, different models were constructed. First, a clin-
ical risk model was built. The clinical risk model included parameters of
different validated risk scores, the Framingham Risk Score, pooled cohort
equations, and SCORE. Parameters included in the clinical risk model
were age, gender, body mass index, systolic blood pressure, smoking sta-
tus, and presence of diabetes, the use of antihypertensive medication,
total cholesterol levels, HDL cholesterol levels, and triglyceride levels.
Second, a protein-based model was constructed using the measured
plasma proteins only. A third model was formed by stacking the clinical
risk parameters with the protein parameters. The proteins and clinical
parameters were allowed to compete in the formation of this model. All
three models were validated in the validation cohort without
adjustments.
Next, considering the long-term follow-up of subjects and the fact that
proteins are subject to change due to lifestyle and medical interventions,
we assessed the optimal time point of prediction of acute myocardial in-
farction in the derivation cohort using Markov-Chain Monte Carlo tech-
niques. For this optimal time point of prediction, similar to the long-term
modelling, a clinical risk model, protein model, and a combined model
were formed. Specifically for this time point, we calculated the net reclas-
sification improvement (NRI) as described by Pencina et al.22 for case–
control studies. Theretofore, we used the acute myocardial infarction
prevalence of the total EPIC-Norfolk cohort in the same period.
In addition, we constructed survival models for both the protein model
and the clinical risk model in the derivation cohort, to compare model
performance across all possible time points. This time-to-event analysis
was performed using identical machine learning techniques as the binary
models, with the implementation of a survival loss function. Inverse prob-
ability of censoring weighting was used to cope with the right-censored
data.23 Using these survival models, time-dependent area under the
curves (AUCs) were calculated with a 2-year interval starting from
3 years up to the median follow-up of 20 years.
Machine learning techniques
All binary models were constructed using the same machine learning
techniques (Figure 1). First, to avoid overfitting of the models, the deriv-
ation data set was split into two sets: a training set of 80% and a test set of
20%. The model was not exposed to data from the 20% test set; this was
only used for the performance measurements. Ten percentage of the
80% training set was used for model refinement before the model per-
formance was tested in the test set. In construction of the models and
identification of the most reliable biomarker signature in our datasets
(both proteomics and clinical), we used stability selection with extreme
gradient boosting. Gradient boosting is a statistical learning technique,
which produces a non-linear model in the form of an ensemble of weak
prediction tree-based models. It builds the model in a stage-wise fashion,
and it generalizes them by allowing optimization of an arbitrary differenti-
able loss function. The extreme gradient boosting classification algorithm
optimizes a cost function by iteratively choosing a weak hypothesis that
points in the negative gradient direction.20,21 Using a fivefold cross-
validation by random reshuffling of the training set, overfitting was
avoided. For increased confidence, this procedure was repeated multiple
times on a completely reshuffled dataset. Furthermore, the method was
coupled with a rigorous stability selection procedure to ensure the reli-
ability and robustness of the obtained parameters.24 Finally, we applied a
permutation (randomization test) to evaluate statistical validity of the
results,25 since standard univariate significance tests cannot be applied to
the used models due to the large number of features. The permutation
test comprised 1000 reruns of the model, every time randomly permut-
ing the output variable (presence/absence of the event). By evaluating the
distribution of all the results obtained in these simulations and comparing
it to the true outcomes, we computed statistical significance associated
with the joint panel of the selected markers. We also reported
4 R.M. Hoogeveen et al.
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importance scores for each of the proteins that demonstrate preferences
of model when constructing non-linear prediction function based on the
selected biomarkers. Python version 3.7 (www.python.org), with pack-
ages Numpy, Scipy, and Scikits-learn, was used for machine learning mod-
els and visualizations.
Results
Study populations
Baseline characteristics of individuals from the derivation and valid-
ation cohort are provided in Table 1. In short, cases in the derivation
cohort were more likely to have traditional risk factors for CV dis-
ease (older, more likely male, smokers and had higher blood pressure
and cholesterol levels). In the validation cohort, cases were more
likely to be older, to smoke, and have high blood pressure. In all par-
ticipants, 368 preselected proteins were measured; proteins were
excluded if >_90% of the values were below lower limit of detection.
Due to the latter and overlap between the panels, the final analysis
included 333 unique proteins (Supplementary material online, Table
S1).
Prediction of acute myocardial infarction
Prediction of myocardial infarction using a machine learning model
consisting of 50 plasma proteins over a median follow-up of 20 years
resulted in an receiver operating characteristic (ROC) AUC of
0.754 ± 0.011 (permutation test P= 0.0099; Figures 2 and 3A and
Table 2). In comparison, the use of the clinical risk model resulted in
an ROC AUC of 0.730± 0.015 (permutation test P= 0.0099).
Combining the protein panel with clinical risk model resulted in an
ROC AUC of 0.764 ± 0.015 (permutation test P= 0.0099). The
biomarker model was superior to the clinical risk model (P< 0.001).
The combined protein and clinical risk model showed a small incre-
mental AUC of 0.01 in comparison with the protein model alone.
Using Markov-Chain Monte Carlo techniques, the optimal time point
for prediction was found at 1132 days (3 years), which included 66
acute myocardial infarctions and all 411 non-myocardial infarction
controls. Of the 50 proteins that were selected for the3 years pre-
diction model, 33 overlapped with the original 20 years model
(Supplementary material online, Figure S1). Focusing on the events
occurring within 3 years after baseline blood withdrawal, the ROC
AUC increased to 0.803 ± 0.093 (permutation test P= 0.0145;
Figure 3B), as opposed to 0.732± 0.164 (permutation test P= 0.0099)
using the clinical risk model. The combination of the protein and clin-
ical risk parameters resulted in an ROC AUC of 0.808 ± 0.085 (per-
mutation test P= 0.0178). Now, the biomarker model was superior
to the clinical risk model with an incremental AUC of 0.07
(P= 0.025) but not to the combination of the protein and clinical risk
model (P= 0.721). For the short-term prediction, the NRI of the pro-
tein model in comparison to the clinical risk model was 6.6%. In the
survival analysis, the protein model resulted in a mean time-
dependent AUC of 0.717 ± 0.027, which was superior across all time
points compared to the clinical risk model mean AUC of
0.653± 0.031 (P< 0.001; Supplementary material online, Figure S2).
Validation of the predictive value
We validated the discriminatory ability of the 50 proteins from the
derivation cohort in the validation cohort. First, we investigated the
ability of the proteins to predict subclinical atherosclerosis. The pre-
diction was relatively poor with an ROC AUC of 0.648± 0.056 (per-
mutation test P= 0.0297; Supplementary material online, Figure S3).
....................................................................................................................................................................................................................
Table 1 Baseline characteristics
EPIC—case (n5 411) EPIC—control (n5 411) PLIC—case (n5 351) PLIC—control (n5351)
Age (years) 66 ± 7.8 62 ± 7.7 55 ± 8.1 54 ± 8.2
Male gender 282 (68.6) 254 (61.8) 117 (33.3) 116 (33.0)
BMI (kg/m2) 26.8 ± 3.7 26.6 ± 3.6 26.9 ± 4.2 26.4 ± 3.2
Systolic blood pressure (mmHg) 144 ± 19 136 ± 17 134 ± 17 130 ± 16
Diastolic blood pressure (mmHg) 86 ± 12 83 ± 11 84 ± 9 82 ± 9
Current smoker 61 (15) 22 (5.4) 78 (22.2) 56 (16.0)
Total cholesterol (mg/dL)a 250 ± 47 243 ± 43 225 ± 39 220 ± 38
HDL cholesterol (mg/dL)a 50 ± 14 53 ± 15 55 ± 15 58 ± 15
LDL cholesterol (mg/dL)a 164 ± 41 157 ± 39 147 ± 37 142 ± 35
Triglycerides (mg/dL)b 168 (115–239) 151 (106–222) 102 (66–143) 86 (61–119)
hsCRP (mg/L) 2.1 (1.1–5.0) 1.3 (0.7–2.9) — –
HbA1c (%) 5.77 ± 1.28 5.38 ± 0.79 — —
Antidiabetic drug use baseline — — 3 (0.9) 2 (0.6)
Lipid lowering drug use baseline 9 (2.2) 6 (1.5) — —
Antihypertensive drug use baseline 150 (36.5) 75 (18.2) 92 (26.2) 68 (19.4)
Median time of follow-up (years) 15.1 (7.7–19.6) 20.5 (19.6–21.2) 11.1 (10.9–11.3) 11.1 (11.0–11.3)
Values are n (%), mean ± standard deviation, or median (IQR) for skewed data.
BMI, body mass index; EPIC, European Prospective Investigation; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; IQR, inter-quartile range; LDL, low-
density lipoprotein; PLIC, Progressione della Lesione Intimale Carotidea.
aTo convert to mmol/L, divide with 38.7.
bTo convert to mmol/L, divide with 88.6.
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from CV events vs. the 351 participants with no signs of atheroscler-
osis, the protein model resulted in an ROC AUC of 0.705 ± 0.071
(permutation test P= 0.0099; Figure 3C), compared to the clinical risk
model ROC AUC 0.609± 0.057 (permutation test P= 0.0700;
Table 2). The protein model was significantly better than the clinical
risk model in the validation cohort (P< 0.001). The combined protein
and clinical risk model resulted in an ROC AUC of 0.692± 0.090
(permutation test P= 0.0099), which was not better than the protein
model alone (P= 0.618).
Figure 2 Importance plot of proteins. Relative importance of 50 proteins predictive in derivation cohort.
Figure 3 Receiver operating characteristics of prediction models. (A) Prediction of events with protein, clinical risk, and combined model in deriv-
ation cohort. (B) Short-term prediction (<3 years) of events with protein, clinical risk, and combined model in derivation cohort. (C) Prediction of
events with protein, clinical risk, and combined model in validation cohort. AUC, area under the curve; ROC, receiver operating characteristic.
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Discussion
Using targeted proteomics, we show that a panel of 50 proteins out-
performs the clinical risk model in predicting the risk of myocardial in-
farction (<3 years) in a primary prevention setting with an AUC
increase in the ROC curve of 0.07. Improvement in predicting CV
events during the entire (median) 20-year follow-up period was sig-
nificant, albeit modest. In an external independent validation cohort,
the predictive value of the protein panel for CV events was con-
firmed and superior to the clinical risk model (incremental AUC
0.10). Survival analysis showed superiority of the protein model to
the clinical risk model at all tested time points (P< 0.001).
Collectively, these data show that a novel proteomic panel offers a
significant improvement in CV risk discrimination compared to a clin-
ical risk model based on traditional risk factors (Take-home figure).
Protein-based risk prediction
outperforms traditional risk factors
We substantiate the predictive value of a panel comprising 50 pro-
teins for a first MI with an ROC AUC of 0.754± 0.011, using targeted
proteomics. Although outperforming the prediction by the clinical
risk model (P< 0.001), the AUC increase of 0.02 is very modest.
Interestingly, the prediction of earlier MI (within 3 years after baseline
blood sampling) using the plasma protein panel performed better,
with an incremental ROC of 0.07. Where genetic prediction models
....................................................................................................................................................................................................................
Table 2 Receiver operating characteristic area under the curve of prediction
Derivation cohort Derivation (<3 years) Validation cohort
Protein model 0.754 ± 0.011 0.803 ± 0.093 0.705 ± 0.071
Clinical risk model 0.730 ± 0.015 0.732 ± 0.164 0.609 ± 0.057
Combined clinical and protein model 0.764 ± 0.015 0.808 ± 0.085 0.692 ± 0.090
Average receiver operating characteristics area under the curve of the prediction models.
Take-home figure Derivation and validation of a plasma proteomic model improves cardiovascular risk prediction in a primary prevention
setting, demonstrating the potential of a proteomics panel to further refine risk assessment. CV, cardiovascular; NPX, Normalized Protein
eXpression; PEA, proximity extension assay.
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are advocated to predict lifelong risk, the ability of our protein model
particularly in shorter-term risk prediction most likely highlights the
property of plasma proteomics to reflect a more proximate time-
frame. Confronted with continuous changes in lifestyle as well as
medical interventions during the course of a life, repeated proteome-
based risk estimation as a ‘liquid health check’ may help to further im-
prove lifetime risk estimation.26 The prediction of predominantly
short-term MI substantiates our previous findings that proteomics
also predicts the presence of high-risk plaques in patients, which are
closely associated with an increased risk for ensuing MI.27 Previous
cohort studies have also reported benefit of proteins in risk predic-
tion. The Framingham Heart Study investigators evaluated a panel of
85 plasma proteins in relation to CV events in primary care setting.28
Using a multi-marker analysis, they reported eight biomarkers pre-
dictive for incident CVD, which on top of clinical parameters
achieved an ROC of 0.758. These data are in line with data reported
for the prediction of recurrent coronary events, where a panel of 9
out of 1130 proteins modestly improved risk prediction (AUC 0.70)
compared to the clinical risk algorithm (AUC 0.64).11
Proteins predictive of cardiovascular
events
Based on previous findings,13 we used targeted proteomics using pro-
teins relating to cardiometabolic disease, CV disease, and inflamma-
tion/immune responses. The majority of proteins in our model were
related to immune system response; particularly proteins involved in
chemotaxis, migration, apoptosis, and angiogenesis. Most of the pro-
teins found to predict early vs. all events overlapped (33/50). Several
proteins merit further attention considering their marked contribu-
tion to the final model. Growth Differentiation Factor 15 (GDF-15)
was the protein with the largest contribution. In chronic diseases,
GDF-15 produced by leukocytes has been shown to enhance inflam-
mation.29 Other prominent candidates involve the N-terminal pro-B-
type natriuretic peptides and BNP, which are established markers
for heart failure and predictors of CV events.30 There is also a
preponderance of inflammatory proteins, comprising metallo
proteinase-12 (MMP-12), TRAIL receptor 2 and interleukin-6. These
proteins, involved in matrix degradation, apoptosis and inflam
mation induction, reflect major pathways contributing to atheroscler-
otic lesion formation and destabilization. Interestingly, there is clear
overlap in proteins and pathways when comparing our data to previ-
ous CVD-proteomic studies. Thus, GDF-15 was also identified as a
predictive candidate in previous studies.13,28,31 Similarly,
the relevance of plasma MMP1211,13,32,33 and various chemo/cyto-
kines28,31,33 underscore consistency between these studies.
Validation in the Progressione della
Lesione Intimale Carotidea cohort
Validation of our findings was performed in the primary prevention
PLIC cohort, in which both repetitive non-invasive measures for ath-
erosclerosis and CV events were collected during an 11-year follow-
up.34 The 50-protein model from the derivation cohort showed rea-
sonable prediction of CV events with an ROC AUC of 0.705 ± 0.071,
with an incremental AUC of 0.10 compared to the clinical risk model
in the PLIC cohort (ROC AUC of 0.609± 0.057). We also assessed
the value of the proteomic model to predict the presence of
subclinical atherosclerotic lesions assessed using ultrasound, reveal-
ing an ROC AUC of 0.648± 0.056. The failure of plasma proteomics
to accurately predict the presence of subclinical atherosclerosis is in
line with the findings in the derivation cohort, where the protein sig-
nature performed better for early/mid-term CV events than for long-
term events.
Clinical perspective
In previous studies, adding single plasma markers to clinical risk algo-
rithms resulted in only a modest improvements of risk predic-
tion.35,36 Here, we report a marked improvement in CVD risk
prediction using a targeted proteomics approach. The hurdles for
using proteomic panels in clinical practice have been largely removed
with the advent of affordable high-throughput technology requiring
only minimal amounts of plasma. More importantly, machine learning
technology further facilitates the use of complex, massive data (such
as proteomics) in clinical decision making.8,9 The need for better dis-
crimination of subjects at highest CV event risk is underscored by the
advent of expensive medication in CVD preventive therapy beyond
generic statins, among which PCSK9-antibodies,37,38low-dose Xa in-
hibition,39 SGLT2 inhibitors,40,41 and GLP1 agonists.42,43 Whereas a
high-risk proteomic panel holds a promise to help identify higher-risk
subjects, it is tempting to speculate that pathway analysis of the
proteomic signature may also allow for the guidance of what medica-
tion to use in specific patient categories.6 This concept is under-
scored by the CANTOS study, where predominantly CRP
responders demonstrated CV benefit of interleukin 1 beta-antibody
administration.44 However, this concept needs further validation
with special emphasis on relationships between biomarkers and pro-
tein network analysis.6,45 Hypothetically, the development of a
targeted-proteomic based risk score might enable a more patient-
tailored approach for the primary prevention of CV events.
Strengths and limitations
The combination of proteomics with machine learning technology is
highly promising.8,9 Machine learning technology can process data
that surpasses the capacity of traditional statistics and the human
brain to comprehend.9 One of the most important differences is that
our predictive machine learning model is based on multiple proteins
in a panel, which collectively leads to a reliable prediction. Using ma-
chine learning, non-linear relationships and interactions among pro-
teins are taken into account, in contrast to univariate models that
only address up- and/or down-regulation of individual proteins. In the
current analyses, we refitted the clinical risk factors from the
Framingham risk score and SCORE to best fit our cohort data, aiming
to improve the performance of traditional risk factors. By applying
analogous machine learning methods for the traditional risk factors,
the observed superiority of our protein model over the clinical risk
model is distinct.
Several potential limitations deserve closer attention. First, the
cohorts used in this study were collected over a decade ago. Over
the years, risk factor management has improved, plaque characteris-
tics have altered, and patient characteristics have changed.46 Second,
our validation cohort had a limited number of CVD events.
However, validation of our protein model on these events was rea-
sonable and the model outperformed the clinical risk model in the
validation cohort, in an even stronger manner than in the derivation
8 R.M. Hoogeveen et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa648/5893663 by U
niversity of C
am
bridge user on 28 O
ctober 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
cohort. Third, we used targeted rather than untargeted proteomics
in our study. Proteins were preselected as potential biomarkers for
CV disease, since clinical verification, rather than protein discovery
was the goal in our study. Despite analysing a broad range of proteins,
we may have missed other predictors of CV event risk due to the use
of targeted proteomics only. As a result, we may have underesti-
mated the true potential of proteomics in CV risk estimation. Fourth,
in contrary to other primary prevention risk scores such as the
Pooled Cohort Equation,4 our constructed models do not predict
lifetime risk, which could be useful in primary prevention patients
characterized by a relatively low short-term CV risk, such as in sub-
jects below 50 years of age. However, in the present study, we pre-
ferred shorter-term prediction for several reasons. Most
importantly, the mean age of both our derivation and validation
cohorts was well above the age of 50 years, resulting in a higher
short-term risk even in primary prevention. Furthermore, diagnostic
improvement in detecting high-risk patients is currently needed to
make decisions on initiating novel medication on top of routine regi-
mens, and for these decisions, relatively short-time horizons are rou-
tinely used. Fifth, the samples in the derivation cohort were non-
fasting, while the samples in the validation cohort were collected
after an overnight fast. Despite this difference, the protein model per-
formed comparable in the validation cohort. Finally, the current anal-
yses were performed in subjects primarily from European ancestry.
Hence, the predictive power remains to be validated in different
ethnicities.
Conclusions
In primary prevention, proteome-based risk prediction significantly
outperforms prediction using clinical risk factors in predicting the risk
of acute myocardial infarction and CV events, especially in the first
3 years. In the midst of novel, expensive drugs, prediction of individual
CVD risk and treatment benefit is increasingly important. Further
large prospective studies will have to determine the true value of
proteome-based risk scores in primary prevention.
Supplementary material
Supplementary material is available at European Heart Journal online.
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